Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis.

Br J Cancer · 2005 · PMC2361536 · PMID 16288305

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

However, a recent meta-analysis of rEpo used in both patients with anemia and without anemia suggests a strong trend towards a survival advantages in favor of the use of rEpo ( Bohlius et al , 2005 ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.